Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITIGATE: Icosapent Ethyl for Viral URI in ASCVD
NCT04505098Phase 4Terminated
- Sponsor
- Kaiser Permanente
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of omega-3-acid triglycerides in viral upper respiratory tract infection, sponsored by Kaiser Permanente. Started Aug 2020; status: terminated.
02
Drugs
omega-3-acid triglycerides
03
Conditions
viral upper respiratory tract infection
Beyond the preview
Go deeper on NCT04505098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505098.